Primary Epstein–Barr virus infection and probable parvovirus B19 reactivation resulting in fulminant hepatitis and fulfilling five of eight criteria for hemophagocytic lymphohistiocytosis  by Karrasch, Matthias et al.
International Journal of Infectious Diseases 28 (2014) 143–146Case Report
Primary Epstein–Barr virus infection and probable parvovirus
B19 reactivation resulting in fulminant hepatitis and fulﬁlling ﬁve
of eight criteria for hemophagocytic lymphohistiocytosis
Matthias Karrasch a,*, Jo¨rg Felber b, Peter M. Keller b, Christine Kletta c, Renate Egerer a,
Ju¨rgen Bohnert a, Beate Hermann a, Wolfgang Pﬁster a, Bernhard Theis d, Iver Petersen d,
Andreas Stallmach b, Michael Baier a
a Institute of Medical Microbiology, University Hospital, Friedrich-Schiller-University, Erlanger Allee 101, 07743 Jena, Germany
bDepartment of Internal Medicine IV, University Hospital, Friedrich-Schiller-University, Jena, Germany
c Emergency Room, University Hospital, Friedrich-Schiller-University, Jena, Germany
d Institute of Pathology, University Hospital, Friedrich-Schiller-University, Jena, Germany
A R T I C L E I N F O
Article history:
Received 27 March 2014
Received in revised form 21 July 2014
Accepted 5 August 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Epstein–Barr virus
Parvovirus B19
Hemophagocytic lymphohistiocytosis
S U M M A R Y
A case of primary Epstein–Barr virus (EBV) infection/parvovirus B19 reactivation fulﬁlling ﬁve of eight
criteria for hemophagocytic lymphohistiocytosis (HLH) is presented. Despite two coinciding viral
infections, massive splenomegaly, and fulminant hepatitis, the patient had a good clinical outcome,
probably due to an early onset form of HLH with normal leukocyte count, normal natural killer (NK) cell
function, and a lack of hemophagocytosis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Secondary hemophagocytic lymphohistiocytosis (HLH) is a rare
and often fatal disease in which activated and dysregulated
macrophages, cytotoxic T-cells, and natural killer (NK) cells cause
different major clinical problems. Clinical guidelines have been
established to aid in the ﬁeld of HLH diagnosis.1 Various herpes
viruses, such as Epstein–Barr virus (EBV), cytomegalovirus (CMV),
and parvovirus B19 (PVB19) are known triggers for secondary
HLH.2 Key deﬁning clinical and laboratory ﬁndings are fever,
splenomegaly, cytopenias, hypertriglyceridemia, hemophagocy-
tosis, low or absent NK cell activity, high ferritin levels, and
elevated soluble interleukin (IL)-2 receptor.1 Early and aggressive
HLH treatment using immunosuppressive drugs is crucial, despite
the high side-effect proﬁle of the drugs used. It is unclear whether
an early onset form of HLH can also be treated with less toxic
regimens in order to achieve a complete clinical response.* Corresponding author. Tel.: +49 (0)3641 9393611.
E-mail address: matthias.karrasch@med.uni-jena.de (M. Karrasch).
http://dx.doi.org/10.1016/j.ijid.2014.08.003
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).2. Materials and methods
PVB19 serology was performed using Biotrin (Dublin, Ireland).
PVB19 IgG and IgM Western blot was done with recomLine
(Mikrogen, Neuried, Germany). Quantitative PVB19 PCR from
whole blood was carried out using Cobas (Roche, Basel,
Switzerland). Polyvalent EBV IgG analysis was done using
Enzygnost (Siemens). EBV-IgM Western blot analysis was per-
formed with recomLine (Mikrogen). Heterophile antibodies were
detected by Paul–Bunnell test (Biokit, Barcelona, Spain) and
quantitative EBV PCR was performed using LightCycler (Roche).
3. Case report
A 27-year-old male patient was admitted to hospital with
exacerbated fatigue, jaundice, fever, and a change in colour of his
stool and urine for 2 days. On clinical examination, the patient had
fever, white swollen tonsils, enlarged cervical lymph nodes, light
stool, dark urine, and a palpable liver 6 cm below the rib cage.
Abdominal ultrasound showed an enlarged liver without signs of
localized disease or portal vein congestions (Figure 1), a greatlyciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. Abdominal ultrasound of the liver (upper panel, 1–3) and spleen (lower panel, 4–6). No change was seen in liver size from visit 1 (Image 1) to visit 4 (Image 3), and no
detectable portal vein thrombosis was seen on Doppler ultrasound (Image 2). Signiﬁcant shrinkage was seen in longitudinal spleen size (187 mm, visit 1 (Image 4) to 132 mm,
visit 4 (Image 5)), and the development of spleen infarction was seen on visit 4 (21.8 mm diameter, Image 6).
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lymph nodes.
Liver enzymes (alanine aminotransferase 10.24 mmol/l, aspar-
tate aminotransferase 5.38 mmol/l, gamma-glutamyl transferase
13.36 mmol/l)), total bilirubin (176 mmol/l), ferritin (10 063.4 mg/
l), lactate dehydrogenase (17.68 mmol/l), AP (alkaline phospha-
tase) (13.36 mmol/l), serum electrophoresis gamma globulin
fraction (22.8%), quantitative IgM concentration (2.75 g/l), and
soluble IL-2 receptor concentration (>6000 U/ml) were elevated;
ﬁbrinogen (1.5 g/l) was reduced. Blood analysis showed a
leukocyte count at the upper limit of normal, with normocytic
and normochromic anaemia, monocytosis (10E9/l), elevated CD3+
(5462 cells/ml) and CD8+ (4752 cells/ml), and a reduced CD19+
lymphocyte count (88 cells/ml). Serology was negative for
hepatitis C virus antibodies, hepatitis B surface antigen, HIV,
herpes simplex virus, varicella zoster virus, and CMV antibodies.
PVB19 IgG and IgM (Biotrin) were detected, with IgG antibodies
showing high avidity. PVB19 IgG and IgM Western blot
(recomLine) was positive for several antigens (e.g. anti-VP and
anti-NS-1). Quantitative PVB19 PCR (Cobas) from whole blood
revealed 136 IU/ml. Polyvalent EBV IgG was elevated (Enzyg-
nost) and EBV IgM Western blot analysis (recomLine) showed
anti-IEA and anti-EA, but no anti-EBNA-1 signal. Anti-VCA (p18)
IgG antibodies are usually produced later in the course of
EBV infection and can substitute for the lack of anti-EBNA-1 IgG,
which was found negative in this patient. Heterophile antibodies
were detected with the Paul–Bunnell test (Biokit) and quantita-
tive EBV PCR (LightCycler) was positive with 1.10  106 copies/ml
(Table 1).
Histological and cytological bone marrow examinations were
performed to rule out direct signs of hemophagocytosis. The
histological bone marrow analysis showed a markedly hypercel-
lular bone marrow with diffuse proliferation of all three cell lines.
Immunostaining for CD3+ T-lymphocytes was done, revealing
inﬁltration of the bone marrow by polyclonal T-lymphocytic cells.
Cytological analysis showed preserved maturation but an increase
in early forms of erythro- and granulopoiesis, as well as an increase
in eosinophils and maturating megakaryopoiesis, intermingledwith small lymphocytes. There were no direct signs of hemopha-
gocytosis in the bone marrow analyzed (Figure 2).
4. Discussion
The patient suffered from an acute primary EBV infection (high
EBV viral load, detection of heterophile antibodies, anti-EBNA-1
and anti-VCA negative, anti-EA and anti-IEA positive in EBV-
speciﬁc IgG/IgM Western blot) with resulting EBV-associated
hepatitis. As a consequence of elevated PVB19 IgM and detection of
PVB19 high avidity IgG antibodies, a PVB19 PCR was performed in
which we found a 10-fold higher PVB19 concentration than the
lower limit detection of PVB19 PCR according to the manufac-
turer’s test speciﬁcity (PVB19 viral load of 14.1 IE/ml positive in
98.1% of cases; in an internal validation, this test was even more
sensitive with 7.5 IE/ml). Laboratory results therefore indicated a
probable PVB19 reactivation.
Five out of eight criteria for HLH3,4 were found to be positive
(elevated soluble IL-2 receptor, elevated ferritin, splenomegaly,
fever, and low ﬁbrinogen), whereas other important HLH criteria
were found to be negative (normal leukocyte count, normal NK cell
function, no direct signs of hemophagocytosis). We found reactive
inﬁltrating CD3+ T-lymphocytes in the bone marrow but did not
check for EBV encoded RNA (EBER-1) or EBV latent membrane
protein 1 (LMP-1) due to the HLH diagnosis. Treatment consisted of
high-dose corticosteroids (100 mg/day for 1 week) to which the
patient responded immediately. A repeat examination after 14 days
showed a clear decrease in spleen size with a small spleen
infarction (Figure 1), reduced EBV viral load (Table 1), negative
PVB19 quantitative PCR (Table 1), and a patient in improved
general condition without fever or lymph node swellings.
In conclusion, despite two probable coinciding viral infections
and clinical symptoms, the patient had a good clinical outcome
using only high-dose corticosteroid as immunosuppressive thera-
py. The favourable outcome might be explained by an early onset
form of HLH lacking direct signs of hemophagocytosis and
displaying a normal leukocyte count and normal NK cell function
early in the disease process.5 On the other hand, clinical signs and
Table 1
Viral load and serological parameters of Epstein–Barr virus (EBV) and parvovirus B19 (PVB19) during the course of clinical infection
Visita EBVb PVB19c
Viral load
(1) copies/ml
(2) copies/mg
DNA
IgG ELISA,
U/ml
IgG
immunoblot
IgM
immunoblot
Viral load,
IU/ml
IgG ELISA,
index
IgM ELISA,
index
IgG
immunoblot
IgM
immunoblot
V1 (1) 1.10  106
(2) 42 049
58.0 EBNA1 (p72) –
VCA (p18) –
IEA ++
EA (p54) +++
EBNA1 (p72) –
VCA (p23) –
IEA +
p138 (+)
p54 (+)
136.0 5.36 1.93 VP-2p +++
VP-N +++
VP-1S +++
VP-2r +++
VP-C (+)
NS-1 +++
VP-2p (+)
VP-N +++
VP-1S ++
VP-2r +++
VP-2r 
VP-C 
NS-1 
V2 (1) 1.18  105
(2) 4120
NA EBNA1 (p72)
VCA (p18) –
IEA +++
EA (p54) +++
EBNA1 (p72) 
VCA (p23) 
IEA +
p138 (+)
p54 (+)
NA NA NA NA NA
V3 (1) 1.27  105
(2) 5815
36.0 NA NA NA NA NA NA NA
V4 (1) 4.90  103
(2) 514
33.0 NA NA <7.5 6.75 1.91 Vp-2p +++
VP-N +++
VP-1S +++
VP-2r +++
VP-C (+)
NS-1 +++
Vp-2p (+)
VP-N ++
VP-1S (+)
VP-2r 
VP-C 
NS-1 
VCA, virus capsid antigen; EA, early antigen; IEA, immediate early antigen; EBNA, EBV-speciﬁc nuclear antigen.
a V = visit, in weekly intervals.
b EBV Western blot: EBNA-1 (p72), VCA (p18), VCA (p23) are markers of chronic infection; EA (p54), EA (p138), IEA are markers of acute infection.
c PVB19 Western blot: VP-2 (VP-2p/VP-2r) is the main capsid antigen; VP-N is the N-terminal fragment of VP-1; NS-1 is the non-structural protein.
Figure 2. Bone marrow histology (Images 1, 2, and 4) and cytology (Image 3). Images 1 and 2 show marked hypercellular bone marrow with diffuse proliferation of all three
cell lines (haematoxylin and eosin stain). Image 3 shows preserved maturation but an increase in early forms of erythro- and granulopoiesis and an increase of eosinophils and
maturating megakaryopoiesis, intermingled with small lymphocytes. Image 4 shows polyclonal T-lymphocytic inﬁltrations (CD3 immunostaining).
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represent a normal immune reaction to the viral infections reported.
This case shows the clinical difﬁculties in the differential diagnosis and
subsequent treatment of HLH under the current deﬁnition.
Funding: No funding was provided for this case report.
Conﬂict of interest: The authors do not report any conﬂict of
interest.
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